|
|
|
| home > white papers > The Power of Execution in Clinical Research - Medpace |
|
|
 WHITE PAPERS |
|
Medpace
|
|
The Power of Execution in Clinical Research
|
|
Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach – combined with therapeutic expertise, regulatory know how, and global presence – delivers clinical studies with an industry recognized track record.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Schrödinger Announces Acquisition of XTAL BioStructures, Inc.
NEW YORK--(BUSINESS WIRE)--Jan. 18, 2022-- Schrödinger, Inc. (Nasdaq:
SDGR), whose physics-based software platform is transforming the way
therapeutics and materials are discovered, today announced the
acquisition of XTAL BioStructures, Inc., a private company based in the
Greater Boston area that provides structural biology services, including
biophysical methods, protein production and purification, and X-ray
crystallography, to the pharmaceutical and biotechnology industries.
More info >> |
|
 |
White Papers |
 |
|
Keeping Abreast of the Competitive Environment in Clinical Development
Thomson Reuters
Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >> |
|
|
|
